ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0650

Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria

Session Information

  • CKD Mechanisms - 2
    October 22, 2020 | Location: On-Demand
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2103 CKD (Non-Dialysis): Mechanisms

Authors

  • Renaud, Lauren, Synlogic, Cambridge, Massachusetts, United States
  • Lubkowicz, David, Synlogic, Cambridge, Massachusetts, United States
  • Reeder, Pip, Synlogic, Cambridge, Massachusetts, United States
  • Bergeron, Chris, Synlogic, Cambridge, Massachusetts, United States
  • Chen, Zhibin Courtney, Synlogic, Cambridge, Massachusetts, United States
  • James, Michael J., Synlogic, Cambridge, Massachusetts, United States
  • Cantarella, Pasquale, Synlogic, Cambridge, Massachusetts, United States
  • Charbonneau, Mark, Synlogic, Cambridge, Massachusetts, United States
  • Shmueli, Ron, Synlogic, Cambridge, Massachusetts, United States
  • Gao, Jr, Synlogic, Cambridge, Massachusetts, United States
  • Isabella, Vincent, Synlogic, Cambridge, Massachusetts, United States
  • Perreault, Mylene, Synlogic, Cambridge, Massachusetts, United States
Background

Enteric hyperoxaluria (EH) is a metabolic disease that results from excessive absorption of oxalate from dietary sources. Increased oxalate levels can lead to the formation of kidney stones and, ultimately, to kidney failure. EH occurs most frequently in patients with underlying gastrointestinal disorders, including inflammatory bowel disease, short bowel syndrome, or individuals who have undergone bariatric surgery. There is a high unmet need for new EH therapies, as a low oxalate diet is the only option currently available to patients. Synlogic is developing a novel Synthetic BioticTM medicine for the treatment of EH, designated as SYNB8802.

Methods

SYNB8802 is an engineered bacterium derived from Escherichia coli Nissle 1917 (EcN) that has been engineered to metabolize oxalate to formate and CO2 in the gastrointestinal tract.

Results

Inoculation of SYNB8802 into minimal media showed significant consumption of oxalate and production of formate as compared to un-engineered (EcN) bacterial strain. When administered concomitantly with 13C-oxalate to healthy mice, SYNB8802 decreased the urinary recovery of 13C-oxalate, indicative of its ability to consume oxalate in vivo. In healthy non-human primates (NHP) administered approximately 400 mg of dietary oxalate, SYNB8802 lowered the urinary recovery of oxalate and 13C-oxalate in a dose dependent manner by up to 75% as compared to vehicle. In addition, Synlogic has developed a mathematical model that predicts clinically meaningful reductions in urinary oxalate in EH patients.

Conclusion

Overall, SYNB8802 represents a promising new approach for the treatment of enteric hyperoxaluria.